

# Thorsten Verch

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6613716/thorsten-verch-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30  
papers

1,148  
citations

13  
h-index

31  
g-index

31  
ext. papers

1,289  
ext. citations

3.2  
avg, IF

3.7  
L-index

#	Paper	IF	Citations
30	Analytical Quality by Design, Life Cycle Management, and Method Control.. <i>AAPS Journal</i> , <b>2022</b> , 24, 34	3.7	1
29	Monoclonal Antibody Reagent Stability and Expiry Recommendation Combining Experimental Data with Mathematical Modeling. <i>AAPS Journal</i> , <b>2020</b> , 22, 145	3.7	1
28	Principles of vaccine potency assays. <i>Bioanalysis</i> , <b>2018</b> , 10, 163-180	2.1	10
27	Evaluation of a digital dispenser for direct curve dilutions in a vaccine potency assay. <i>Journal of Immunological Methods</i> , <b>2017</b> , 442, 20-28	2.5	3
26	Development and Characterization of an HPV Type-16 Specific Modified DNA Aptamer for the Improvement of Potency Assays. <i>Analytical Chemistry</i> , <b>2017</b> , 89, 3554-3561	7.8	15
25	Replacing antibodies with modified DNA aptamers in vaccine potency assays. <i>Vaccine</i> , <b>2017</b> , 35, 5495-5502	4.2	24
24	2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays). <i>Bioanalysis</i> , <b>2017</b> , 9, 1967-1996	2.1	33
23	A semi-universal assay platform to quantitate vaccines with potential applications for biotherapeutics. <i>Bioanalysis</i> , <b>2016</b> , 8, 2523-2535	2.1	
22	Mitigation of microtiter plate positioning effects using a block randomization scheme. <i>Analytical and Bioanalytical Chemistry</i> , <b>2016</b> , 408, 3969-79	4.4	9
21	Reduction of dilution error in ELISAs using an internal standard. <i>Bioanalysis</i> , <b>2016</b> , 8, 1451-64	2.1	5
20	Quality-by-Design: As Related to Analytical Concepts, Control and Qualification <b>2015</b> , 479-520		1
19	Application of quality by design and statistical quality control concepts in immunoassays. <i>Bioanalysis</i> , <b>2014</b> , 6, 3251-60	2.1	3
18	Quality by design for a vaccine release immunoassay: a case study. <i>Bioanalysis</i> , <b>2013</b> , 5, 2531-45	2.1	5
17	Miniaturized immunoassays: moving beyond the microplate. <i>Bioanalysis</i> , <b>2012</b> , 4, 177-88	2.1	23
16	Comparison of the NIDS <sup>®</sup> rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2011</b> , 63, 150-9	1.7	6
15	Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2011</b> , 63, 227-35	1.7	35
14	Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab. <i>Bioanalysis</i> , <b>2011</b> , 3, 2107-17	2.1	1

13	Validation of preclinical pharmacokinetic and immunogenicity assays for an anti-PCSK9 antibody. <i>Journal of Immunoassay and Immunochemistry</i> , <b>2011</b> , 32, 296-317	1.8	2
12	Pharmacokinetic immunoassay methods in the presence of soluble target. <i>Journal of Immunological Methods</i> , <b>2010</b> , 361, 75-81	2.5	13
11	Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. <i>Technology in Cancer Research and Treatment</i> , <b>2009</b> , 8, 323-32	2.7	23
10	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. <i>Gynecologic Oncology</i> , <b>2008</b> , 108, 402-8	4.9	506
9	Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 1520-6	4	22
8	Anticancer Vaccine Strategies <b>2008</b> , 481-511		2
7	Immunotherapeutic Strategies against Cancer using <i>Listeria monocytogenes</i> as a Vector for Tumor Antigens <b>2007</b> , 113-129		
6	MESOMARK(®) in vitro diagnostic test for mesothelioma. <i>Expert Opinion on Medical Diagnostics</i> , <b>2007</b> , 1, 137-42		12
5	MESOMARK: a potential test for malignant pleural mesothelioma. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 666-72	5.5	110
4	Mesothelin variant 1 is released from tumor cells as a diagnostic marker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 1014-20	4	93
3	<i>Listeria monocytogenes</i> -based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. <i>Infection and Immunity</i> , <b>2004</b> , 72, 6418-25	3.7	46
2	Immunization with a plant-produced colorectal cancer antigen. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 92-9	7.4	27
1	Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. <i>Journal of Immunological Methods</i> , <b>1998</b> , 220, 69-75	2.5	117